Cell News and Research

RSS

Study confirms blood-stage infection is due to population mixing and disease evolution

In a paradigm changing discovery, Plasmodium vivax (P. vivax) malaria has been identified in a population historically thought to be resistant to the disease, those who do not express the Duffy blood group protein on their red blood cells, according to researchers from Case Western Reserve University School of Medicine, Pasteur Institute, and the Madagascar Ministry of Health.

16 Mar 2010

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Treating non-osteoporotic compression fractures in patients with multiple myeloma, a blood cancer, shows that the use of vertebroplasty-a minimally invasive treatment performed by interventional radiologists using imaging guidance that stabilizes collapsed vertebrae with the injection of medical-grade bone cement into the spine-results in a reduction of pain, medication usage and disability, according to researchers in the largest study of its kind at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

EHSI signs profit sharing deal with Celulas Genetica

Emerging Healthcare Solutions, Inc. announced today that it locked down an option for a profit participation deal with biotech firm Celulas Genetica. Celulas Genetica works to develop new major medical solutions using adult stem cell research.

16 Mar 2010

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

16 Mar 2010

Research reveals molecular mechanism of DNA repair

New research led by scientists at the University of Essex has given an insight into how the body finds damage in the DNA code to repair it.

16 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas. The data were presented at the PCSK9 Conference: From Gene to Therapeutics held in Nantes, France from March 11-13, 2010.

15 Mar 2010

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have discovered that "microtentacles," or extensions of the plasma membrane of breast cancer cells, appear to play a key role in how cancers spread to distant locations in the body. Targeting these microtentacles might prove to be a new way to prevent or slow the growth of these secondary cancers, the scientists say.

15 Mar 2010

ATS releases new clinical policy statement on CCHS

The American Thoracic Society has released a new official clinical policy statement on congenital central hypoventilation syndrome (CCHS), a disorder of respiratory and autonomic nervous system (ANS) regulation. The ANS regulates reflexive acts, including heart rate and blood pressure, digestion, body temperature and pain perception.

15 Mar 2010

MPP cell population: A new potential target for treating infections and allergies

Millions of people in both the developing and developed world may benefit from new immune-system research findings from the University of Pennsylvania School of Veterinary Medicine.

15 Mar 2010

Study reveals molecular mechanism of pancreatic cancer

UCSF scientists have discovered how a mutated gene known as Kras is able to hijack mouse cells damaged by acute pancreatitis, putting them on the path to becoming pancreatic cancer cells.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

New laboratory technique may help prioritize cancer drugs for clinical trials

Improving on traditional screening tests for potential anti-cancer drugs, scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with the body's normal cells.

15 Mar 2010

Puzzle baffled scientists for centuries - why some birds appear to be half male and half female solved

A puzzle that has baffled scientists for centuries - why some birds appear to be male on one side of the body and female on the other - has been solved by researchers.

15 Mar 2010

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference.

15 Mar 2010

New findings shed light on how genetic damage to muscle cell proteins can lead to nemaline myopathy

New findings that shed light on how genetic damage to muscle cell proteins can lead to the development of the rare muscle-wasting disease, nemaline myopathy, are reported today (15 March) in the Biochemical Journal.

15 Mar 2010

Cell News and Research

Study confirms blood-stage infection is due to population mixing and disease evolution

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

EHSI signs profit sharing deal with Celulas Genetica

Gene defects could become targets for new personalised treatments for bowel cancer

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Research reveals molecular mechanism of DNA repair

CytRx plans five Phase 2 clinical trials with oncology drug candidates

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

ATS releases new clinical policy statement on CCHS

MPP cell population: A new potential target for treating infections and allergies

Study reveals molecular mechanism of pancreatic cancer

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

New laboratory technique may help prioritize cancer drugs for clinical trials

Puzzle baffled scientists for centuries - why some birds appear to be half male and half female solved

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

New findings shed light on how genetic damage to muscle cell proteins can lead to nemaline myopathy

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo